key: cord-0810812-ryj83uw3
authors: Vanshylla, Kanika; Di Cristanziano, Veronica; Kleipass, Franziska; Dewald, Felix; Schommers, Philipp; Gieselmann, Lutz; Gruell, Henning; Schlotz, Maike; Ercanoglu, Meryem S.; Stumpf, Ricarda; Mayer, Petra; Zehner, Matthias; Heger, Eva; Johannis, Wibke; Horn, Carola; Suárez, Isabelle; Jung, Norma; Salomon, Susanne; Eberhardt, Kirsten Alexandra; Gathof, Birgit; Fätkenheuer, Gerd; Pfeifer, Nico; Eggeling, Ralf; Augustin, Max; Lehmann, Clara; Klein, Florian
title: Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
date: 2021-05-03
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.04.015
sha: 4de5769ff2b2540bae4c7443f1d1960610928423
doc_id: 810812
cord_uid: ryj83uw3

Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2-neutralization, with these ‘elite neutralizers’ also possessing SARS-CoV-1 cross-neutralizing IgG. Multivariate statistical modeling revealed age, symptomatic infection, disease severity and gender as key factors predicting SARS-CoV-2 neutralizing activity. A loss of reactivity to the virus spike protein was observed in 13% individuals 10 months after infection. Neutralizing activity had half-lives of 14.7 weeks in serum versus 31.4 weeks in purified IgG, indicating a stable long-term IgG antibody response. Our results demonstrate a broad spectrum in the initial SARS-CoV-2-neutralizing antibody response, with sustained antibodies in most individuals for 10 months after mild COVID-19.

In this study, we set out to provide a deeper understanding of the neutralizing antibody Other participants were lost in follow-up or did not reach the respective study visit at 114 the time of our analysis. Anti-spike IgG was quantified by ELISA and chemiluminescent 115 immunoassays (CLIA) and the NAb response to SARS-CoV-2 was analyzed using both 116 serum dilutions as well as purified IgG to precisely quantify neutralizing activity (Fig. S1A-D) .

In total, 4,516 measurements were collected for visit 1 with another 2,279 subsequent 118 measurements for visit 2-4 to determine the SARS-CoV-2 antibody response for 10 months NAb isotype in serum. To further determine the predictive value of IgG binding to the S 143 protein for SARS-CoV-2 neutralization, we performed an S1-reactive ELISA (Euroimmun) on 144 all samples of visit 1. 82.8% and 70.2% of individuals possessed spike-reactive IgG (Fig. 2D , 145 E) and IgA Abs, respectively (Fig. S1E) . Of note, the serum only neutralizers had very low 146 serum neutralization levels with GeoMean ID 50 of 24, with 47.6% of this fraction 147 demonstrating IgA reactivity. Anti-spike IgG levels were directly proportional to IgG NAb IC 50 7 Finally, we determined the fraction of individuals lacking any detectable antibody response.

To this end, we combined the results of different IgG and IgA assays detecting binding to 152 SARS-CoV-2 S1, S1/S2, and N as well as three neutralization assays (Fig. 2G) . Out of the 153 166 anti-S1-IgG negative (12.7%) or equivocal (4.6%) individuals, we found binding 154 antibodies in 62.0% in at least one of four assays and neutralizing activity in 54.2% in at least 155 one of three assays (Fig. 2G, H) . Combining these results and accounting for assay-156 specificity (see methods) we show that only 5.6%-7.3% of individuals do not mount a 157 detectable antibody response against SARS-CoV-2. Notably, while only 3.6% (1 of 28) of 158 hospitalized patients and 4.9% (43 of 877) of individuals with mild symptoms lacked anti-159 SARS-CoV-2 antibodies, 22.7% (10 of 44) asymptomatic individuals were negative for a 160 detectable antibody response in at visit 1 (Fig. 2I) . We conclude that 92.7-94.4% of 161 individuals naturally infected with SARS-CoV-2 mount an antibody response against the virus 162 within the first 12 weeks. Among those, we detected a broad variation in neutralizing activity 163 with approximately 3% generating a highly potent serum and IgG NAb response.

Age, symptoms and disease severity predict SARS-CoV-2 neutralization 166 Next, we analyzed how age, disease severity, gender, and the presence of pre-existing 167 conditions correlate with the anti-spike antibody and SARS-CoV-2 neutralizing response 168 ( Fig. 3A, Fig. S2 ). The IgG NAb response was significantly higher in older individuals (p 169 <0.0001), with participants >60 years comprising 7.7% of elite-and 42.8% of high-170 neutralizers (Fig. 3A) . Hospitalized patients had significantly higher NAb activity compared to 171 individuals with symptoms (p = 0.0008) and asymptomatic individuals (p = 0.0003), out of 172 which 43.2% (25 of 44) of the latter lacked detectable IgG NAbs (Fig. 3A) 

3A). Similar to IgG NAb activity, serum neutralizing activity and anti-spike antibodies were 177 J o u r n a l P r e -p r o o f 8 also higher in older individuals, patients with a more severe course of disease, and males 178 ( Fig. S2A-C) 188 Similar to IgG neutralization, age, time since disease onset, fever during acute infection, 189 male gender, disease severity and diarrhea during infection were highly predictive of serum 190 ID 50 (Fig. S3A) . Additionally, we built a Bayesian network model to determine the feature 191 dependencies and how they predict the SARS-CoV-2 IgG neutralizing response (Fig. 3D) 192 and serum neutralization response (Fig. S3B) . In addition, we investigated the possible 193 effect of viral load obtained from naso-/oro-pharyngeal swabs at the time of diagnosis on the 194 antibody response at study visit 1, but no correlation was found (Fig. S3C, D) . In summary, 

CoV-2 as well as SARS-CoV-1 pseudovirus (Fig. 4A) . Neutralization of SARS-CoV-2 208 pseudovirus against authentic virus correlated closely in all groups with authentic virus 209 (spearman r = 0.79; Fig. 4B ). SARS-CoV-1 neutralization was not observed in non-and low- (Fig. 4D) . IgG from elite neutralizers was potent against all 218 tested SARS-CoV-2 strains, including both S1 and S2 mutants as well as variants (BAVP1, 219 DRC94) carrying the D614G mutation (Fig. 4E) . Intriguingly, testing the neutralizer groups 220 against recent SARS-CoV-2 variants of concern, B1.1.7 and B1.351 (Fig. 4F) , revealed no 221 significant effect on neutralizing activity against the B1.1.7 variant for all 5 groups (Fig. 4F) .

On the other hand, the B1.351 variant caused almost a 20-fold drop in GeoMean IgG IC 50 in 223 elite neutralizers, with many average-low neutralizers losing neutralizing capacity against this 224 variant (Fig. 4F) . We conclude, that individuals mounting a potent SARS-CoV-2 NAb 

were male and female, respectively, and 41.8% had been hospitalized (Fig. S4A) . Anti-spike

IgG and IgA could be detected in some people within the first week after disease onset, with

IgA levels starting to decline by week 4 (Fig. S4B) . Out of the 8 individuals that were closely 

In order to assess longevity of humoral immunity following SARS-CoV-2 infection, we applied Table S1 ). While the 248 detection of S1-reactivity stays equal at first and second visit (86%), the fraction of 249 individuals that are reactive for S1-reactive antibodies decays to 79% (7% drop from visit 1) 250 at the third visit and to 73% (13% drop from visit 1) at visit 4 (9-10 months post disease 251 onset).

NAb activity was longitudinally monitored for 102 individuals from visit 1 (median 6.4 weeks 253 post infection) up to visit 4 (median 37.9 weeks post infection) ( Fig. 5D-H) . Regression 254 modeling showed that serum NAb titers had a short half-life of 14.7 weeks (Fig. 5D ) 255 compared to a much longer 31.4-week half-life for IgG NAb titers (Fig. 5G) . Out of 102 256 individuals, 88.2% had serum NAb activity at visit 1 whereas only 79.4% had NAb activity 257 remaining at visit 4 (Fig. 5F) . The overall fraction of IgG neutralizers changed from 87.3% to 258 J o u r n a l P r e -p r o o f 11 71.6% between visit 1 and 4. The most dramatic change from Geo Mean IC 50 of 40.14 g/ml 259 to 166.6 g/ml was detected in elite/high neutralizers from visit 1 to 4, 76% of whom lost their 260 'elite' or 'high' status. 35% of average/low neutralizers at visit 1 became negative at visit 2 261 (Fig. 5I) . Approximately 9% of individuals did not develop any NAbs and remained serum 262 and IgG-negative throughout the observation period. Overall, only 3% of individuals lost 263 detectable antibody responses against SARS-CoV-2 between 1.5-and 10-months post 264 infection ( Fig. S4D and E) . Amongst the SARS-CoV-1 cross neutralizers, there was a an 265 almost 4-fold drop in IgG neutralizing activity against SARS-CoV-2 between 7.4-and 19.4-266 weeks post disease onset. However, reactivity to SARS-CoV-1 did not change in most 267 individuals (Fig. S4F) . Finally, we also preformed regression modeling to estimate half-life 268 based on age, gender, pre-conditions and disease severity (Fig. S5) . We found that females 269 had more stable antibody levels than males and younger individuals had more sustained 

The authors declare no competing interests. 

To select features that are predictive for the log 10 response in a multivariate analysis (Fig. 3   609 and Fig. S3) , forward stepwise regression was applied, using the p-value from a likelihood 610 ratio test (R function lmtest::lrtest) as selection criterion in each step. The final multiple linear 611 regression model (Fig. 3 and Fig. S3 ) includes only features that show a significant model 612 improvement (alpha=0.05) in the feature selection phase. To study the interplay of the 613 different features regarding their relationship with the response (Fig. 3d) J o u r n a l P r e -p r o o f

Vanshylla et al. report longitudinal antibody kinetics in a mainly mild COVID-19 convalescent cohort of 963 individuals. There is broad variation in the initial response with older age and disease severity predicting higher SARS-CoV-2 neutralizing activity. Neutralizing IgG antibodies are detectable up to 10 months in the majority of individuals.

Duration of humoral immunity to Galvan

Persistence of COVID-19 Symptoms after Recovery in 669 Mexican Population

COVID-19-neutralizing 672 antibodies predict disease severity and survival

Nextstrain: real-time tracking of pathogen evolution

Temporal dynamics in viral shedding and transmissibility of COVID-19

SARS-CoV-2 Cell Entry 681 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

6-month consequences of COVID-19 in patients discharged from hospital: a 683 cohort study

A systematic 686 review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, 687 and association with severity

Clinical features of patients infected with 2019 novel coronavirus in

Persistence and decay of human 693 antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 694 patients

An mRNA Vaccine 697 against SARS-CoV-2 -Preliminary Report

Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche

Role of IgM and IgA Antibodies in the 703 Neutralization of SARS-CoV-2. medRxiv

Tracking Changes in SARS-CoV-2 707 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

SARS-CoV-2 vaccines in development

Longitudinal Isolation of Potent 712 Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Antibody-guided vaccine 715 design: identification of protective epitopes

Antibody responses to SARS-CoV-2 in patients with COVID-19

Serological Assays Estimate Highly 721 Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients

ggeffects: Tidy Data Frames of Marginal Effects from Regression Models

Antibody Status and Incidence of 727 SARS-CoV-2 Infection in Health Care Workers

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent 730 therapeutic antibody

Correlates of protection against SARS-CoV-2 in 733 rhesus macaques

Investigation of novel SARS-COV-2 variant, Variant of Concern 202012/01. Public 736 Health England

Single-shot Ad26 vaccine protects against SARS-739

CoV-2 in rhesus macaques

Longitudinal symptom dynamics of COVID-19 742 infection

Antibody responses to viral infections: a 744 structural perspective across three different enveloped viruses

SARS-CoV-2 seroprevalence and neutralizing activity in 747 donor and patient blood

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity

Prevalence of Asymptomatic SARS-CoV-2 Infection : A 752 Narrative Review

Mapping Neutralizing and 755 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-756 Guided High-Resolution Serology

Cross-Sectional Evaluation of Humoral 759 Responses against SARS-CoV-2 Spike

Convergent antibody responses

CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and 765 protection from disease in a small animal model

Defining the features and duration of antibody 768 responses to SARS-CoV-2 infection associated with disease severity and outcome

Transmission of 2019-nCoV Infection from 772 an Asymptomatic Contact in Germany

Antigen-Specific Adaptive Immunity 775 to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

COVID-19 vaccine BNT162b1 elicits human antibody 779 and TH1 T cell responses

Learning Bayesian Networks with thebnlearnRPackage

Longitudinal observation and decline of 784 neutralizing antibody responses in the three months following SARS-CoV-2 infection in 785 humans

Human immunodeficiency virus type 1 elite 788 neutralizers: individuals with broad and potent neutralizing activity identified by using a 789 high-throughput neutralization assay together with an analytical selection algorithm

The Method of 'Right and Wrong Cases' ('Constant Stimuli') without

Rapid Generation of 795 Neutralizing Antibody Responses in COVID-19 Patients

Emergence and rapid spread of a new severe 798 acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike 799 mutations in South Africa

The circulating SARS-CoV-2 spike 803 variant N439K maintains fitness while evading antibody-mediated immunity

Robust neutralizing antibodies

CoV-2 infection persist for months